Valuation: Haleon plc

Market Cap 32.17B 43.5B 37.66B 35.2B 60.62B 4,149B 61.57B 413B 162B 2,076B 163B 160B 6,913B P/E 2026 *
19x
P/E 2027 * 16.8x
Enterprise Value 39.03B 52.78B 45.69B 42.71B 73.56B 5,034B 74.71B 501B 197B 2,518B 198B 194B 8,388B EV / Sales 2026 *
3.43x
EV / Sales 2027 * 3.25x
Free-Float
98.47%
Yield 2026 *
2.21%
Yield 2027 * 2.46%
1 day-1.14%
1 week+0.80%
Current month+0.52%
1 month+0.94%
3 months+10.27%
6 months-8.79%
Current year-2.56%
1 week 360.5
Extreme 360.5
374.6
1 month 354.1
Extreme 354.1
384.2
Current year 317.8
Extreme 317.8
416.1
1 year 274.4
Extreme 274.4
416.1
3 years 274.4
Extreme 274.4
419.5
5 years 241.17
Extreme 241.1735
419.5
10 years 241.17
Extreme 241.1735
419.5
Manager TitleAgeSince
Chief Executive Officer 59 2021-07-21
Director of Finance/CFO 57 2024-10-31
Chief Tech/Sci/R&D Officer 63 2025-07-31
Director TitleAgeSince
Director/Board Member 59 2022-05-22
Chairman 71 2025-12-31
Director/Board Member 59 2022-07-17
Date Insider Type Main position Quantity % Market Cap.
6/30/26 Free

Chief Financial Officer

283,193 0.0032%
6/30/26 Tax

Chief Financial Officer

-133,301 0.0015%
2/12/26 Free

General Counsel

31 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-0.33%+0.80%+2.82%+8.64% 43.5B
+3.90%+9.86%+96.91%+136.30% 1,098B
+0.99%+2.91%+51.05%+52.06% 631B
+0.78%+1.17%+25.21%+63.74% 438B
-0.38%+4.80%+51.42%+39.79% 368B
+0.07%+1.85%+34.81%+39.99% 298B
-0.78%+4.26%+9.78%+7.42% 251B
+1.52%+10.12%+44.75%+59.20% 226B
+0.92%+1.27%-5.23%-50.94% 209B
-0.11%+1.46%+11.43%+66.32% 165B
Average +0.93%+3.00%+32.29%+42.25% 372.78B
Weighted average by Cap. +1.76%+4.79%+51.62%+67.84%

Financials

2026 *2027 *
Net sales 11.39B 15.4B 13.34B 12.47B 21.47B 1,469B 21.8B 146B 57.36B 735B 57.84B 56.58B 2,448B 11.87B 16.06B 13.9B 12.99B 22.37B 1,531B 22.72B 152B 59.78B 766B 60.29B 58.97B 2,551B
Net income 1.7B 2.29B 1.99B 1.86B 3.2B 219B 3.25B 21.77B 8.54B 109B 8.62B 8.43B 365B 1.92B 2.6B 2.25B 2.1B 3.62B 248B 3.68B 24.64B 9.67B 124B 9.75B 9.54B 413B
Net Debt 6.86B 9.28B 8.04B 7.51B 12.94B 885B 13.14B 88.08B 34.56B 443B 34.85B 34.09B 1,475B 6.42B 8.69B 7.52B 7.03B 12.11B 828B 12.3B 82.43B 32.34B 414B 32.62B 31.91B 1,380B
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (31.4%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - pain relief medicines (23.2%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - respiratory medicines (17%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (15.3%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.; - medicines for digestive health (8.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - other (4.2%). Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.6%), North America (35.1%), and Asia/Pacific (23.3%).
Employees
24,535
Date Price Change Volume
26-08-11 GBX 364.50 -0.19% 436,672
26-08-10 GBX 365.20 -1.14% 10,044,621
26-08-07 GBX 369.40 -0.32% 19,877,858
26-08-06 GBX 370.60 +1.34% 23,238,101
26-08-05 GBX 365.70 +2.24% 18,893,239
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.652GBP
Average target price
4.208GBP
Spread / Average Target
+15.23%

Quarterly revenue - Rate of surprise